MHRA: Discontinuation of Pipothiazine (Piportil) depot
There is a global shortage of the active pharmaceutical ingredient pipotiazine palmitate and the manufacturer, Sanofi, is therefore unable to provide further supplies of Piportil Depot injection.
Based on current estimates it is anticipated that the following Piportil Depot® formulations will no longer be available: from the end of March 2015:
- Piportil Depot® (pipotiazine palmitate) 10 x 1ml (50mg/ml) amp
- Piportil Depot® (pipotiazine palmitate) 10 x 2ml (50mg/ml) amp
No new patients should be initiated on pipotiazine palmitate and patients currently prescribed pipotiazine palmitate injection (Piportil Depot®) must be transferred to alternative treatments.
By Kuebi = Armin Kübelbeck (Own work) [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons